Parsaclisib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Parsaclisib
Accession Number
DB14867
Type
Small Molecule
Groups
Investigational
Description

Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).

Structure
Thumb
Synonyms
  • INCB050465
Categories
Not Available
UNII
OS7097575K
CAS number
1426698-88-5
Weight
Average: 432.88
Monoisotopic: 432.1476798
Chemical Formula
C20H22ClFN6O2
InChI Key
ZQPDJCIXJHUERQ-QWRGUYRKSA-N
InChI
InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1
IUPAC Name
(4R)-4-{3-[(1S)-1-{4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl}ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one
SMILES
CCOC1=C(C=C(Cl)C(F)=C1[C@@H]1CNC(=O)C1)[C@H](C)N1N=C(C)C2=C1N=CN=C2N

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
64835232
BindingDB
272573

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Breast Cancer / Colorectal Cancer (CRC) / CRC (Colorectal Cancer) / Endometrial Cancer / Head and Neck Carcinoma / Head and Neck Squamous Cell Carcinoma (HNSCC) / Lung Cancers / Malignant Neoplasm of Pancreas / Melanoma / Microsatellite Unstable (MSI) Colorectal Cancer / MMR-deficient Tumors / Non-Small Cell Lung Carcinoma (NSCLC) / Pancreatic Ductal Adenocarcinoma / RCC (Renal Cell Carinoma) / Renal Cell Adenocarcinoma / SCCHN (Head and Neck Squamous Cell Carcinoma) / Small Cell Lung Cancer (SCLC) / Transitional Cell Carcinoma of the Genitourinary Tract / Triple Negative Breast Cancer (TNBC) / Tumors, Solid / UC (Urothelial Cancer)1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / Relapsed or Refractory Follicular Lymphoma1
1Not Yet RecruitingBasic ScienceBreast Cancer / HER2 Positive Breast Cancers / Neoplasms, Breast / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentAnn Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage II Follicular Lymphoma / Ann Arbor Stage II Marginal Zone Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Follicular Lymphoma / Ann Arbor Stage III Marginal Zone Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Follicular Lymphoma / Ann Arbor Stage IV Marginal Zone Lymphoma / Diffuse Large B-Cell Lymphoma (DLBCL) / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / Indolent Non-Hodgkin's Lymphomas1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentRefractory Diffuse Large B Cell Lymphoma / Relapsed, Diffuse Large B-cell Lymphoma1
1RecruitingTreatmentUnresectable or Metastatic Solid Tumors1
1TerminatedTreatmentAdvanced Solid Tumors / Tumors, Solid1
1, 2Active Not RecruitingTreatmentB-Cell Malignancies1
1, 2TerminatedTreatmentAdvanced Malignancies / Metastatic Cancers / Tumors, Solid1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / Refractory Marginal Zone Lymphoma / Relapsed Marginal Zone Lymphoma1
2CompletedTreatmentPrimary Sjögren's Syndrome1
2Not Yet RecruitingTreatmentIndolent Non-Hodgkin's Lymphomas1
2Not Yet RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentAgnogenic Myeloid Metaplasia / MPN (Myeloproliferative Neoplasms)1
2RecruitingTreatmentAutoimmune Hemolytic Anemia1
2RecruitingTreatmentFollicular Lymphoma (FL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
2WithdrawnTreatmentPemphigus Vulgaris (PV)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0462 mg/mLALOGPS
logP2.67ALOGPS
logP1.79ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.37ChemAxon
pKa (Strongest Basic)3.56ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area107.95 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity123.54 m3·mol-1ChemAxon
Polarizability42.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolidines
Sub Class
Phenylpyrrolidines
Direct Parent
Phenylpyrrolidines
Alternative Parents
Pyrazolo[3,4-d]pyrimidines / Phenoxy compounds / Phenol ethers / Chlorobenzenes / Fluorobenzenes / Alkyl aryl ethers / Aminopyrimidines and derivatives / Pyrrolidine-2-ones / Aryl fluorides / Imidolactams
show 14 more
Substituents
2-pyrrolidone / 3-phenylpyrrolidine / Alkyl aryl ether / Amine / Amino acid or derivatives / Aminopyrimidine / Aromatic heteropolycyclic compound / Aryl chloride / Aryl fluoride / Aryl halide
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on May 20, 2019 08:31 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates